{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:33:36Z","timestamp":1786620816284,"version":"build-2736575974"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":201,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Momentum Data"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>While RA and menopausal hormone treatment (MHT) are known to increase the risk of venous thromboembolism (VTE), how MHT influences VTE incidence within the RA population has not been well-characterised. This study aimed to evaluate whether MHT is associated with an increased risk of VTE in peri- and postmenopausal women with RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective, matched cohort study using UK primary care data from the Clinical Practice Research Datalink (CPRD) Aurum, linked to secondary care, from 2001 to 2021. Women ages 40\u201379\u2009years with RA initiating MHT were matched to women with RA not initiating MHT. VTE incidence rates were calculated and Cox proportional hazards models adjusted for risk factors estimated the MHT-associated VTE risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2187 women with RA initiating MHT were matched to 8205 unexposed controls. VTE incidence was higher among MHT users [6.49 (95% CI 4.28, 9.44) per 1000 person-years vs 3.30 (95% CI 2.44, 4.36)]. MHT use was associated with a 92% increased risk of VTE in RA [adjusted hazard ratio (aHR) 1.92 (95% CI 1.19, 3.12)], primarily driven by a higher risk of deep vein thrombosis [DVT; aHR 2.26 (95% CI 1.26, 4.05)].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MHT use in peri- and postmenopausal women with RA is associated with a 2-fold increased risk of VTE, particularly DVT, relative to unexposed controls. Individualised risk assessment and monitoring are advised, taking into account the patient\u2019s clinical context. Clinicians should balance MHT benefits against thrombotic risks and consider alternatives or preventive strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rap\/rkag087","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:29:31Z","timestamp":1784633371000},"source":"Crossref","is-referenced-by-count":0,"title":["Exploring the risk of venous thromboembolism in women with rheumatoid arthritis initiating menopausal hormone treatment in England"],"prefix":"10.1093","volume":"10","author":[{"given":"Eva","family":"Henning","sequence":"first","affiliation":[{"name":"Pfizer UK Ltd , Tadworth,","place":["UK"]},{"name":"School of Biological Sciences, Faculty of Biology Medicine and Health, University of Manchester , Manchester,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulraj S","family":"Matharu","sequence":"additional","affiliation":[{"name":"Pfizer UK Ltd , Tadworth,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Czachorowski","sequence":"additional","affiliation":[{"name":"Pfizer UK Ltd , Tadworth,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saqib","family":"Rana","sequence":"additional","affiliation":[{"name":"Pfizer UK Ltd , Tadworth,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzieh","family":"Araghi","sequence":"additional","affiliation":[{"name":"Pfizer UK Ltd , Tadworth,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Alldrit","sequence":"additional","affiliation":[{"name":"Momentum Data UK Ltd , St Albans,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina L","family":"Santos","sequence":"additional","affiliation":[{"name":"Momentum Data UK Ltd , St Albans,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8962-5642","authenticated-orcid":false,"given":"Maya H","family":"Buch","sequence":"additional","affiliation":[{"name":"Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine & Health, University of Manchester , Manchester,","place":["UK"]},{"name":"NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, University of Manchester , Manchester,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1230-2781","authenticated-orcid":false,"given":"James","family":"Galloway","sequence":"additional","affiliation":[{"name":"Versus Arthritis Professor of Rheumatology, Centre for Rheumatic Diseases, King\u2019s College London , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McLean","sequence":"additional","affiliation":[{"name":"Pfizer UK Ltd , Tadworth,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"2026081306463682100_rkag087-B1","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.3390\/jcm9082467","article-title":"Prevention of venous thromboembolism in 2020 and beyond","volume":"9","author":"Nicholson","year":"2020","journal-title":"J Clin Med"},{"key":"2026081306463682100_rkag087-B2","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.3390\/ijms24043169","article-title":"A comprehensive review of risk factors for venous thromboembolism: from epidemiology to pathophysiology","volume":"24","author":"Pastori","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026081306463682100_rkag087-B3","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/moh.0000000000000599","article-title":"Venous thromboembolism in the hormonal milieu","volume":"27","author":"Connell","year":"2020","journal-title":"Curr Opin Hematol"},{"key":"2026081306463682100_rkag087-B4","doi-asserted-by":"publisher","first-page":"e210537","DOI":"10.1530\/ec-21-0537","article-title":"Menopause-associated risk of cardiovascular disease","volume":"11","author":"Anagnostis","year":"2022","journal-title":"Endocr Connect"},{"key":"2026081306463682100_rkag087-B5","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1093\/eurheartj\/ehn299","article-title":"Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis","volume":"29","author":"Sare","year":"2008","journal-title":"Eur Heart J"},{"key":"2026081306463682100_rkag087-B6","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/s0140-6736(03)14066-4","article-title":"Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk","volume":"362","author":"Scarabin","year":"2003","journal-title":"Lancet"},{"key":"2026081306463682100_rkag087-B7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.thromres.2018.06.014","article-title":"Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: a systematic review and meta-analysis","volume":"168","author":"Rovinski","year":"2018","journal-title":"Thromb Res"},{"key":"2026081306463682100_rkag087-B8","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1161\/circulationaha.106.642280","article-title":"Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study","volume":"115","author":"Canonico","year":"2007","journal-title":"Circulation"},{"key":"2026081306463682100_rkag087-B9","doi-asserted-by":"publisher","first-page":"e078784","DOI":"10.1136\/bmj-2023-078784","article-title":"Contemporary menopausal hormone therapy and risk of cardiovascular disease: Swedish nationwide register based emulated target trial","volume":"387","author":"Johansson","year":"2024","journal-title":"BMJ"},{"key":"2026081306463682100_rkag087-B10","doi-asserted-by":"publisher","first-page":"001392","DOI":"10.1136\/rmdopen-2020-001392","article-title":"Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study","volume":"6","author":"Galloway","year":"2020","journal-title":"RMD Open"},{"key":"2026081306463682100_rkag087-B11","doi-asserted-by":"publisher","first-page":"3608","DOI":"10.1093\/eurheartj\/ehx145","article-title":"Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study","volume":"39","author":"Ogdie","year":"2018","journal-title":"Eur Heart J"},{"key":"2026081306463682100_rkag087-B12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1186\/s13075-014-0435-y","article-title":"A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases","volume":"16","author":"Lee","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2026081306463682100_rkag087-B13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s41927-024-00376-9","article-title":"Risk of venous thromboembolism in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"8","author":"Fazal","year":"2024","journal-title":"BMC Rheumatol"},{"key":"2026081306463682100_rkag087-B14","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1136\/annrheumdis-2013-203380","article-title":"Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study","volume":"73","author":"Chung","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026081306463682100_rkag087-B15","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1136\/annrheumdis-2012-201669","article-title":"The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study","volume":"72","author":"Choi","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2026081306463682100_rkag087-B16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/rheumatology\/keaa262","article-title":"The risk and trend of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a general population-based study","volume":"60","author":"Li","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026081306463682100_rkag087-B17","doi-asserted-by":"publisher","first-page":"6224","DOI":"10.1093\/rheumatology\/keaf430","article-title":"Risk of venous thromboembolism in people with RA: a population-based study in the UK","volume":"64","author":"Russell","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026081306463682100_rkag087-B18","doi-asserted-by":"publisher","first-page":"7005","DOI":"10.26355\/eurrev_202111_27249","article-title":"Venous thromboembolism risk in rheumatoid arthritis patients: a systematic review and updated meta-analysis","volume":"25","author":"Hu","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2026081306463682100_rkag087-B19","doi-asserted-by":"publisher","first-page":"105122","DOI":"10.1016\/j.jbspin.2020.105122","article-title":"Risk of venous thromboembolism in rheumatoid arthritis","volume":"88","author":"Ketfi","year":"2021","journal-title":"Joint Bone Spine"},{"key":"2026081306463682100_rkag087-B20","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1136\/annrheumdis-2019-216653","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"79","author":"Sepriano","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026081306463682100_rkag087-B21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/ard-2022-223050","article-title":"Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis","volume":"82","author":"Molander","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2026081306463682100_rkag087-B22","doi-asserted-by":"publisher","first-page":"e1001885","DOI":"10.1371\/journal.pmed.1001885","article-title":"The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement","volume":"12","author":"Benchimol","year":"2015","journal-title":"PLoS Med"},{"key":"2026081306463682100_rkag087-B23","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1093\/ije\/dyz034","article-title":"Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum","volume":"48","author":"Wolf","year":"2019","journal-title":"Int J Epidemiol"},{"key":"2026081306463682100_rkag087-B24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12963-023-00302-0","article-title":"Completeness, agreement, and representativeness of ethnicity recording in the United Kingdom\u2019s Clinical Practice Research Datalink (CPRD) and linked Hospital Episode Statistics (HES)","volume":"21","author":"Shiekh","year":"2023","journal-title":"Popul Health Metr"},{"key":"2026081306463682100_rkag087-B25","doi-asserted-by":"publisher","first-page":"100519","DOI":"10.1016\/j.lanepe.2022.100519","article-title":"Rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis epidemiology in England from 2004 to 2020: an observational study using primary care electronic health record data","volume":"23","author":"Scott","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"2026081306463682100_rkag087-B26","author":"Department for Communities and Local Government","year":"2015"},{"key":"2026081306463682100_rkag087-B27","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/pds.4197","article-title":"Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism","volume":"26","author":"Renoux","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026081306463682100_rkag087-B28","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/j.1538-7836.2005.01268.x","article-title":"Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study","volume":"3","author":"Douketis","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2026081306463682100_rkag087-B29","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/jth.12060","article-title":"The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy","volume":"11","author":"Roach","year":"2013","journal-title":"J Thromb Haemost"},{"key":"2026081306463682100_rkag087-B30","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1253\/circj.CJ-14-1227","article-title":"Hormone therapy and risk of venous thromboembolism among postmenopausal women in Taiwan \u2013 a 10-year nationwide population-based study","volume":"79","author":"Lee","year":"2015","journal-title":"Circ J"},{"key":"2026081306463682100_rkag087-B31","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1097\/gme.0000000000000611","article-title":"Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration","volume":"23","author":"Bergendal","year":"2016","journal-title":"Menopause"},{"key":"2026081306463682100_rkag087-B32","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1111\/j.1538-7836.2010.03839.x","article-title":"Hormone replacement therapy and the risk of venous thromboembolism: a population-based study","volume":"8","author":"Renoux","year":"2010","journal-title":"J Thromb Haemost"},{"key":"2026081306463682100_rkag087-B33","doi-asserted-by":"publisher","first-page":"100135","DOI":"10.1016\/j.rpth.2023.100135","article-title":"Hormone exposure and venous thromboembolism in commercially insured women aged 50 to 64 years","volume":"7","author":"Weller","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"2026081306463682100_rkag087-B34","doi-asserted-by":"publisher","first-page":"k4810","DOI":"10.1136\/bmj.k4810","article-title":"Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"364","author":"Vinogradova","year":"2019","journal-title":"BMJ"},{"key":"2026081306463682100_rkag087-B35","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1111\/j.1538-7836.2012.04919.x","article-title":"Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study","volume":"10","author":"Sweetland","year":"2012","journal-title":"J Thromb Haemost"},{"key":"2026081306463682100_rkag087-B36","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1136\/bmj.39266.425069.AD","article-title":"Main morbidities recorded in the women\u2019s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women","volume":"335","author":"Vickers","year":"2007","journal-title":"BMJ"},{"key":"2026081306463682100_rkag087-B37","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1097\/gme.0b013e3182175e5c","article-title":"Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy","volume":"18","author":"Lalibert\u00e9","year":"2011","journal-title":"Menopause"},{"key":"2026081306463682100_rkag087-B38","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/gme.0000000000000590","article-title":"Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy","volume":"23","author":"Simon","year":"2016","journal-title":"Menopause"},{"key":"2026081306463682100_rkag087-B39","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1161\/atvbaha.109.196022","article-title":"Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study","volume":"30","author":"Canonico","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2026081306463682100_rkag087-B40","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1002\/acr.22039","article-title":"Risk of venous thromboembolism in patients with rheumatoid arthritis","volume":"65","author":"Kim","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026081306463682100_rkag087-B41","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10067-014-2492-7","article-title":"Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"33","author":"Ungprasert","year":"2014","journal-title":"Clin Rheumatol"},{"key":"2026081306463682100_rkag087-B42","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.5001\/omj.2021.25","article-title":"Cardiovascular risk in rheumatoid arthritis: literature review","volume":"36","author":"Hannawi","year":"2021","journal-title":"Oman Med J"},{"key":"2026081306463682100_rkag087-B43","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3390\/medicina59091550","article-title":"Role of inflammatory cytokines in rheumatoid arthritis and development of atherosclerosis: a review","volume":"59","author":"Bedekovi\u0107","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"2026081306463682100_rkag087-B44","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/gme.0000000000002305","article-title":"Does hormone therapy exacerbate other venous thromboembolism risk factors?","volume":"31","author":"Porterfield","year":"2024","journal-title":"Menopause"},{"key":"2026081306463682100_rkag087-B45","doi-asserted-by":"publisher","first-page":"1939","DOI":"10.1007\/s00296-022-05121-4","article-title":"Disease activity as a risk factor for venous thromboembolism in rheumatoid arthritis analysed using time-averaged DAS28CRP: a nested case-control study","volume":"42","author":"Yoshimura","year":"2022","journal-title":"Rheumatol Int"},{"key":"2026081306463682100_rkag087-B46","doi-asserted-by":"publisher","first-page":"38","DOI":"10.31138\/mjr.30.1.38","article-title":"Venous thromboembolism events among RA patients","volume":"30","author":"Mansour","year":"2019","journal-title":"Mediterr J Rheumatol"},{"key":"2026081306463682100_rkag087-B47","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1046\/j.1365-2125.2000.00199.x","article-title":"Validation of the diagnosis of venous thromboembolism in general practice database studies","volume":"49","author":"Lawrenson","year":"2000","journal-title":"Br J Clin Pharmacol"}],"container-title":["Rheumatology Advances in Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumap\/advance-article-pdf\/doi\/10.1093\/rap\/rkag087\/69696861\/rkag087.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/10\/3\/rkag087\/69696861\/rkag087.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumap\/article-pdf\/10\/3\/rkag087\/69696861\/rkag087.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T10:54:19Z","timestamp":1786618459000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumap\/article\/doi\/10.1093\/rap\/rkag087\/8739214"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6,15]]}},"URL":"https:\/\/doi.org\/10.1093\/rap\/rkag087","relation":{},"ISSN":["2514-1775"],"issn-type":[{"value":"2514-1775","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"rkag087"}}